sterile ophthalmic solution is an 8-methoxyfluoroquinolone anti-infective for the treatment of bacterial conjunctivitis. Its chemical name is (±)-1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid, sesquihydrate.
(gatifloxacin ophthalmic solution) 0.5% solution is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms:
Aerobic Gram-Positive Bacteria:
Streptococcus mitis group*
Aerobic Gram-Negative Bacteria:
*Efficacy for this organism was studied in fewer than 10 infections.
Published Studies Related to Zymaxid (Gatifloxacin Ophthalmic)
Aqueous humour penetration of moxifloxocin and gatifloxacin eye drops in different dosing regimens before phacoemulsification surgery. [2011.09]
AIM: To compare the aqueous humour penetration of moxifloxacin 0.5% and gatifloxacin 0.3% eye drops administered in two different dosing regimens during phacoemulsification surgery... CONCLUSION: Moxifloxacin, given in the same dosage, penetrated the aqueous humour better then gatifloxacin during cataract surgery. The penetration of both antibiotics increased significantly when the dosage of the agent was doubled.
Human aqueous humor concentrations of besifloxacin, moxifloxacin, and gatifloxacin after topical ocular application. [2011.06]
PURPOSE: To determine the concentrations of besifloxacin, moxifloxacin, and gatifloxacin in human aqueous humor after topical instillation of commercially available besifloxacin ophthalmic suspension 0.6%, moxifloxacin ophthalmic solution 0.5%, and gatifloxacin ophthalmic solution 0.3%, and to assess these concentrations relative to the minimum inhibitory concentration for 90% of strains (MIC(90)) for each drug against bacterial pathogens identified in recent cases of postoperative endophthalmitis. SETTING: Six clinical sites, United States. DESIGN: Randomized open-label controlled clinical trial... CONCLUSIONS: Based on the aqueous humor drug concentrations measured in this study, it is unlikely that any of the fluoroquinolones tested would be therapeutically effective in the aqueous humor against the most frequently identified drug-resistant staphylococcal isolates from recent cases of postoperative endophthalmitis. FINANCIAL DISCLOSURE: No author has a financial or proprietary interest in any material or method mentioned. Additional disclosures are found in the footnotes. Copyright (c) 2011 ASCRS and ESCRS. Published by Elsevier Inc. All rights reserved.
A prospective randomized evaluation of topical gatifloxacin on conjunctival flora in patients undergoing intravitreal injections. [2009.08]
PURPOSE: We sought to assess the efficacy of 3-day topical gatifloxacin use in combination with povidone-iodine (PVI) versus PVI alone in eliminating conjunctival bacterial flora in patients scheduled to undergo intravitreal (IVT) injection. DESIGN: Prospective, randomized single-blind clinical trial. PARTICIPANTS: We included 129 patients scheduled to undergo 273 IVT injections at California Vitreoretinal Center at Stanford University... CONCLUSIONS: Although 3-day topical gatifloxacin use is effective in reducing the frequency of conjunctival bacterial growth relative to untreated eyes, antibiotic use confers no additional benefit in combination with PVI than eyes receiving PVI alone. This supports that topical PVI is an effective preinjection monotherapy for infection prophylaxis in the setting of IVT injections.
Aqueous humor penetration of gatifloxacin and moxifloxacin eyedrops given in different concentrations in a wick before cataract surgery. [2008.05]
PURPOSE: To determine whether the penetration into the aqueous humor of gatifloxacin (Zymar) and moxifloxacin (Vigamox) eyedrops was affected by altering their concentrations in the dilating mixture in which the wick used to dilate the pupil before cataract surgery was soaked. SETTING: Pasqua Hospital, Regina, Saskatchewan, Canada... CONCLUSIONS: Moxifloxacin penetrated the aqueous humor better than gatifloxacin when given in a wick soaked in the dilating mixture before cataract surgery. Only the penetration of moxifloxacin increased significantly when the volume of the antibiotic in the dilating mixture was doubled. In both groups, only moxifloxacin reached and exceeded the minimum inhibitory concentration levels for the most common ocular pathogens causing endophthalmitis.
Ocular Penetration and Pharmacokinetics of Topical Gatifloxacin 0.3% and Moxifloxacin 0.5% Ophthalmic Solutions After Keratoplasty. [2008.04]
PURPOSE:: To compare the corneal and aqueous penetration and pharmacokinetics of gatifloxacin 0.3% and moxifloxacin 0.5% ophthalmic solutions and their effect on corneal reepithelialization after penetrating keratoplasty... CONCLUSIONS:: Topical preoperative moxifloxacin 0.5% achieved greater corneal and aqueous penetration than did gatifloxacin 0.3%. The clinical significance of this difference is not known. Postoperative use of these agents had similar effects on corneal reepithelialization.
Clinical Trials Related to Zymaxid (Gatifloxacin Ophthalmic)
One Hour Preoperative Gatifloxacin [Completed]
Assessment of the Concentrations of Besifloxacin, Moxifloxacin, or Gatifloxacin in the Aqueous Humor of Subjects [Completed]
This study is being conducted to assess the concentration of besifloxacin, moxifloxacin, or
gatifloxacin in aqueous humor samples collected following topical instillation of the
associated formulation in subjects undergoing cataract surgery.
Non-Inferiority of Gatifloxacin/Prednisolone Association vs Isolated Administration in Prevention of Ocular Infection/Inflammation [Completed]
The purpose of the study is to evaluate the safety and tolerance of the 0. 3% gatifloxacin
and 1. 0% prednisolone acetate association in eye drops in the prevention of infection and
inflammation after refractive surgery (Lasik) and also demonstrate the non-inferiority of
the efficacy of this association compared to the administration of 0. 3% gatifloxacin and
1. 0% prednisolone acetate as isolated eye drops formulations. The study treatment is
randomized, double-masked, with 2 parallel arms. Each patient's participation lasts 29 days,
with 15 days of study treatment administration after the ocular surgery is performed.
Candidates for the study are patients with indication for ocular refractive surgery (Lasik)
for correction of visual acuity.
Concentration of Besifloxacin, Gatifloxacin, and Moxifloxacin in Human Conjunctiva After Topical Instillation [Completed]
The purpose of this study is to assess the concentration of besifloxacin compared to
gatifloxacin and moxifloxacin in human conjunctival tissue, following a single drop of the
drug instilled topically into the study eye. Conjunctival biopsies will be performed at
specified time points, followed by the use of loteprednol etabonate/tobramycin ophthalmic
suspension four times a day for 5 days.
Early Bactericidal Activity of Linezolid, Gatifloxacin, Levofloxacin, Isoniazid (INH) and Moxifloxacin in HIV Negative Adults With Initial Episodes of Sputum Smear-Positive Pulmonary Tuberculosis [Completed]
This study will evaluate the ability of 4 antibiotics to kill the bacteria that cause
tuberculosis (TB). The antibiotics to be studied are linezolid, gatifloxacin, levofloxacin,
and moxifloxacin. All are approved by the Brazilian health authorities to treat infections
caused by germs other than TB. Seventy human immunodeficiency virus (HIV)-negative adults,
aged 18-65 years, who have been newly diagnosed with pulmonary (lung) TB, will participate
in this study. Study volunteers will be given one of the 4 study drugs or a comparison
antibiotic, Isoniazid, which has been used around the world as a standard of care treatment
for TB. Volunteers will stay in the hospital for 10 days and be given a study antibiotic 7
of those days. Blood and saliva samples will be taken. Six weeks later, volunteers will
return for a final health check. All volunteers will receive 6 months of standard
Reports of Suspected Zymaxid (Gatifloxacin Ophthalmic) Side Effects
Toxic Anterior Segment Syndrome (15),
Eye Irritation (3),
Adverse Drug Reaction (3),
Visual Acuity Reduced (2),
Abdominal Pain Upper (2),
OFF Label USE (2),
Eye Inflammation (2),
Condition Aggravated (2), more >>
Page last updated: 2011-12-09